REVENUE (Tables)

3 Months Ended

Jun. 30, 2020

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the six months ended June 30, 2020, is as follows:

	For the Six Months Ended June 30, 2020
	Accounts Receivable		Unbilled Services		Note Receivable		Total
Allowance for credit losses as of December 31, 2019	$	19.0	$	2.3	$	—	$	21.3
Current expected credit losses opening balance impact on retained earnings	1.9		0.2		5.0		7.1
Plus, credit loss expense	9.1		1.9		5.0		16.0
Less, write offs	0.9		0.1		—		1.0
Ending allowance for credit losses	$	29.1	$	4.3	$	10.0	$	43.4

Contract with Customer, Asset and Liability [Table Text Block]

	June 30, 2020		December 31, 2019
Receivables, which are included in accounts receivable	$	730.5	$	771.1
Unbilled services	539.7		483.7
Unearned revenue	471.4		449.2

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment payers/customer groups for the three and six months ended June 30, 2020, and 2019, were as follows:

	For the Three Months Ended June 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	20	%	1	%	—	%	—	%	—	%	—	%	21	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	25	%	1	%	—	%	—	%	—	%	—	%	26	%
Total LCD revenues by payer	59	%	2	%	—	%	—	%	—	%	—	%	61	%
CDD
Biopharmaceutical and medical device companies	18	%	—	%	5	%	4	%	3	%	9	%	39	%
Total revenues	77	%	2	%	5	%	4	%	3	%	9	%	100	%

	For the Three Months Ended June 30, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%
CDD
Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%
Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

	For the Six Months Ended June 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	18	%	1	%	—	%	—	%	—	%	—	%	19	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	25	%	2	%	—	%	—	%	—	%	—	%	27	%
Total LCD revenues by payer	57	%	3	%	—	%	—	%	—	%	—	%	60	%
CDD
Biopharmaceutical and medical device companies	19	%	—	%	5	%	5	%	3	%	8	%	40	%
Total revenues	76	%	3	%	5	%	5	%	3	%	8	%	100	%

	For the Six Months Ended June 30, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%
CDD
Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%
Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

Capitalized Contract Cost [Table Text Block]

	June 30, 2020		December 31, 2019
Sales commission assets	$	32.0	$	28.6
Deferred contract fulfillment costs	13.3		14.9
Total	$	45.3	$	43.5